07:00 , Apr 14, 2014 |  BioCentury  |  Finance

Double vision

Double vision Sofinnova Ventures led NuCana BioMed Ltd. 's $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market. NuCana's ProTide technology adds a phosphoramidate moiety...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Company News

Pacira management update

Pacira Pharmaceuticals Inc. , Parsippany, N.J.   Business: Drug delivery, Neurology, Cancer   Hired: James Scibetta as CFO, formerly CFO of Bioenvision Inc. (now part of Genzyme Corp. )  ...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

Clolar clofarabine: Completed Phase II enrollment

GENZ completed enrollment of 109 treatment-naïve AML patients who are unlikely to benefit from standard induction therapy in the pivotal, U.S. Phase II CLASSIC II trial of IV clofarabine. The agent already is approved to...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

MacroChem management update

MacroChem Corp. (MACM), Wellesley Hills, Mass.   Business: Drug delivery, Infectious, Genitourinary   Hired: David Luci as general counsel, corporate secretary and VP of corporate development, formerly general counsel and EVP at Bioenvision Inc.  ...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Company News

Bioenvision, Genzyme deal

BIVN's stockholders voted to approve the acquisition of the company by GENZ for $5.60 per share, or about $345 million in cash. The price is a penny higher than BIVN's close of $5.59 on Oct....
07:00 , Oct 29, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Company News

Bioenvision, Genzyme cancer, infectious news

The companies filed a joint petition that was granted by the Court of Chancery of the State of Delaware to allow the companies to reconvene BIVN's special meeting of stockholders on Oct. 22 and reopen...
07:00 , Oct 15, 2007 |  BioCentury  |  Finance

Ebb & Flow

Profit-taking by investors after its IPO lock-up expired may have been behind last week's share price dip for cancer and autoimmune company Synta (SNTA), which shed $2.24 (20%) to $8.76 despite announcing a potentially blockbuster...
07:00 , Oct 8, 2007 |  BioCentury  |  Finance

Ebb & Flow

MannKind (MNKD) has pushed itself closer to the top of a short list of biotech companies that have raised in excess of $1 billion without having a product on the market. Last week, the company...
07:00 , Sep 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Gilead (GILD) may be back on an upswing, after a bit of a slide in the early summer, aided last week by an FDA panel's unanimous recommendation for approval of first-in-class HIV treatment Isentress raltegravir...